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Abstract
Signaling mediated by the Epidermal Growth Factor Receptor (EGFR) is crucial in normal development, and aberrant EGFR
signaling has been implicated in a wide variety of cancers. Here we find that the high- and low-affinity interactions between
EGFR and its ligands activate different signaling pathways. While high-affinity ligand binding is sufficient for activation of
most canonical signaling pathways, low-affinity binding is required for the activation of the Signal transducers and
activators of transcription (Stats) and Phospholipase C-gamma 1 (PLCc1). As the Stat proteins are involved in many cellular
responses including proliferation, migration and apoptosis, these results assign a function to low-affinity interactions that
has been omitted from computational models of EGFR signaling. The existence of receptors with distinct signaling
properties provides a way for EGFR to respond to different concentrations of the same ligand in qualitatively different ways.
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Introduction
EGFR is a member of the receptor tyrosine kinase family, which
functions to sense and respond to extracellular signals. Ligand
binding to the extracellular domain of EGFR induces receptor
dimerization, activation of its kinase domain, and phosphorylation
of tyrosine residues in its carboxy terminal tail [1]. Intracellular
proteins containing Src homology 2 (SH2) or phosphotyrosine
binding (PTB) domains bind to these sites of tyrosine phosphor-
ylation [2], initiating a wide variety of signaling cascades including
the Ras/MAPK, PI3K/Akt, PLCc/PKC, and Stat pathways [3].
These signals induce diverse cellular responses, including prolif-
eration, differentiation, migration, survival, and apoptosis.
Scatchard analysis has shown that EGFR binds its ligands with
two distinct affinities and has been thought to indicate the
presence of two distinct populations of receptor [4]. High-affinity
receptors (KD<300 pM) generally constitute ,10% of the total
receptor pool, and low-affinity receptors (KD<2 nM) constitute the
remaining ,90% [5]. These receptors are thought to be derived
from the same transcript and to be identical in amino acid
sequence. It has been suggested that the difference in affinity arises
from differential localization of the receptor in the plasma
membrane [6] or interaction with an ‘‘external site’’, such as
coated-pits [7]. More recently, Macdonald and Pike have
presented evidence that high- and low-affinity binding can be
explained by negative cooperativity, rather than by the existence
of two distinct populations of receptor [8]. Their model predicts
that at low concentrations of ligand, singly occupied dimers will be
most abundant, whereas at high concentrations of ligand, doubly
occupied dimers are also present.
Early reports suggested that most, if not all, cellular responses to
EGFR ligands could be generated by signaling through the small
percentage of high-affinity receptors [9,10]. The fact that very high
ligand concentrations induce different phenotypes [11–16], howev-
er,suggeststhatlow-affinitybindingmayalsoplayanimportantrole
in signaling. Here we demonstrate that high- and low-affinity
interactions between EGFR and its ligands activate distinct
signaling pathways and, further, that the low-affinity interactions
play a crucial role in determining cellular outcome. We find that
most intracellular signaling pathways, including the Ras/MAPK
and PI3K/Akt pathways, are activated upon stimulation of cells
with extremely low concentrations of Epidermal Growth Factor
(EGF) or Transforming Growth Factor-alpha (TGFa). In contrast,
certain proteins, including the Stat transcription factors, cannot be
activated unless a higher concentration of ligand is used. The
concentration of ligand required to activate the Stat proteins
coincides with the low-affinity interaction of EGFR. Moreover, it
coincides with a change in the phenotypic outcome of stimulated
cells. Whether high- and low-affinity receptors are distinct
populations or differ only in their ligand occupancy, our data argue
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15945that high- and low-affinity receptors mediate distinct biological
processes, allowingEGFR toinducequalitatively differentresponses
to the same ligand. Additionally, these findings should inform future
efforts to model the EGFR signaling network and enhance
computational approaches aimed at predicting cell decision
processes mediated by this receptor.
Materials and Methods
Cell Culture
A431, HMEC and MDA-MB-468 cells were obtained from
ATCC (Manassas, VA). The generation of HEK293-EGFR cells
(HEK Flp-In-293 cells expressing ectopic EGFR) has been
described [17]. A431, MDA-MB-468 and HEK293-EGFR cells
were maintained in Dulbecco’s Modified Eagle Medium (DMEM;
Mediatech; Herndon, VA) supplemented with 10% (v/v) Fetal
Bovine Serum (FBS; Hyclone; Logan, UT), 2 mM Glutamine,
100 I.U./mL Penicillin, 100 mg/mL Streptomycin (all from
Mediatech). Culture medium for HEK293-EGFR cells also
included 150 mg/mL Hygromycin B (Invitrogen; Carlsbad, CA).
HMECs were maintained in HuMEC Basal Serum-free Medium
containing the HuMEC supplement and bovine pituitary extract
(Invitrogen). Unless otherwise indicated, cells were serum-starved
for 24 hours before all experiments. For HMECs, serum starvation
is defined as culture in HuMEC Basal Serum-free Medium without
the addition of supplements. To determine cell number, cells were
treated with trypsin, resuspended in PBS, and counted using a
CellometerH AutoT4 (Nexcelom Biosciences; Lawrence, MA).
Lysates and Immunoblotting
Cells were stimulated with EGF (Millipore; Billerica, VA) or
TGFa (PeproTech; Rocky Hill, NJ) at the indicated concentra-
tions. After treatment with growth factors, cells were washed twice
with cold PBS and lysed by adding 0.5 mL of lysis buffer [50 mM
Tris-HCl, 1% NP-40 (v/v), 5 mM EDTA, 1 mM NaF, pH 8.0
supplemented with 10 mM b-glycerol phosphate, 1 mM phenyl-
methanesulfonyl fluoride, 1 mM sodium orthovanadate, 1%
Phosphatase Inhibitor Cocktail II (Sigma; St. Louis, MO), and 1
Complete-Mini Protease Inhibitor Cocktail tablet (Roche Applied
Science; Indianapolis, IN) per 10 mL]. Lysates were cleared by
centrifugation at 20,000 g, 15 min, 4uC. Total protein concentra-
tion was determined using the MicroBCA Protein Assay (Pierce
Biotechnology; Rockford, IL). Prior to immunoblotting, lysates
were boiled in standard SDS gel-loading buffer and loaded onto 8,
10, or 12% polyacrylamide gels (10 mL lysate per lane). After
separation by electrophoresis, the proteins were transferred to
nitrocellulose and the membranes were blocked with 5% nonfat
dry milk (w/v) in Tris-buffered saline (20 mM Tris, 150 mM
NaCl, pH 7.6) containing 0.1% Tween-20 (v/v). Membranes were
probed using rabbit-derived primary antibodies from Cell
Signaling Technologies (Beverly, MA): Akt pS473 (catalogue
number: 9271), Cbl pY774 (3555), CrkL pY207 (3181), Erk
pT202/pY204 (4377), Gab1 pY307 (3234), PLCc1 pY783 (2821),
Shc1 pY239/240 (2434), SHP-2 pY542 (3751), Src pY416 (2101),
Stat1 pY701 (9167), Stat3 pY705 (9131), Stat5 pY694 (9351).
Bands were detected with IRDye 680-labelled goat-anti-rabbit
IgG (LI-COR Biosciences; Lincoln, NE) and imaged using an
Odyssey Infrared Imaging System (LI-COR Biosciences). The
intensity of each band was quantified and then normalized based
on the protein concentration of the lysate.
EGF binding curves
Serum-starved cells or cells growing in 10% serum were treated
with trypsin and washed in PBS. Cells were incubated for 5 h at
4uC in medium containing 0.5% BSA and Alexa Fluor 488-
labeled EGF (Invitrogen) at the indicated concentration. Cells
were then washed, resuspended in 0.5% BSA in PBS, and passed
through 0.7-mm cell strainers. Mean fluorescence intensity was
measured by flow cytometry using an LSRII flow cytometer (BD
Biosciences).
BrdU incorporation assays
Serum-starved cells or cells growing in 10% serum were treated
with EGF for the indicated time. One hour prior to the end of the
incubation, BrdU (BD Biosciences; Franklin Lakes, NJ) was added
to the culture medium to a final concentration of 20 mg/mL. After
a 1-hour incubation, cells were washed twice in cold PBS and
treated with trypsin (Mediatech). Cells were washed twice with
room temperature PBS, resuspended in cold 70% ethanol, and
stored at 4uC in the dark for 2–5 days. After ethanol fixation, cells
were resuspended in 1 mL cold 0.1% Triton X-100, 0.1 M HCl
and incubated on ice for 1 min. Cells were washed in 5 mL of
room temperature denaturation buffer (150 mM sodium chloride,
15 mM sodium citrate), resuspended in 1 mL of denaturation
buffer, and heated at 95uC for 5 min. After cooling on ice for
5 min, the cells were resuspended and added to 5 mL of antibody
dilution buffer (0.1% Triton X-100, 1% bovine serum albumin in
PBS). After centrifugation, cells were stained with FITC-
conjugated anti-BrdU antibody (BD Biosciences) in antibody
dilution buffer and incubated at room temperature for 30 min.
The cells were washed twice with antibody dilution buffer,
resuspended in 0.5% BSA in PBS, and passed through 0.7-mm cell
strainers. BrdU incorporation was assessed by flow cytometry
using an LSRII flow cytometer (BD Biosciences).
Phase-contrast imaging
A431 cells were plated in 6-well plates and either grown in 10%
serum or serum-starved prior to a 12-hour treatment with EGF.
Phase contrast images were generated using an Axiovert 200
microscope (Zeiss; Thornwood, NY) equipped with an environ-
mental chamber (Solent; Segensworth, United Kingdom) that was
held at 37uC throughout all experiments. Images were acquired
with an Orca ERII camera in the high precision (14-bit) mode,
cooled to 260uC.
Results
Different concentrations of EGFR ligands induce
activation of distinct signaling pathways
To explore how different ligand concentrations affect the
activation of EGFR-dependent signaling pathways, we stimulated
serum-starved A431 epidermoid carcinoma cells for five minutes
with twelve concentrations of EGF, ranging from 250 pM to
32 nM. This early time point was chosen because the phosphor-
ylation of many signaling proteins peaks within the first ten
minutes of stimulation and because we wanted to capture early,
receptor-dependent signaling events. The activation of signaling
proteins was monitored by quantitative immunoblotting using
phosphospecific primary antibodies followed by secondary anti-
bodies labeled with infrared fluorophores. Tyrosine phosphoryla-
tion of EGFR, which is a marker for its enzymatic activity, was
found to increase linearly with increasing EGF concentrations and
did not show evidence of saturation even when cells were treated
with 32 nM EGF (Figure 1A). We examined five sites of tyrosine
phosphorylation on EGFR and found that they all behaved
similarly (data not shown).
Downstream of receptor phosphorylation, we examined the
phosphorylation levels of twelve diverse cytoplasmic signaling
High- and Low-Affinity EGFR
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(Erk, Akt, Shc1, CrkL, Cbl, Gab1, PLCc1, Stat1, Stat3, Stat5, Src
and SHP-2), phosphorylation either regulates its activity or
modulates its association with other signaling proteins. Because
antibodies vary in sensitivity, we plotted dose-response curves as a
fraction of the maximal phosphorylation observed for each protein
(Figure 1A). Although we expected to observe differences in the
dose-response curves as signaling proteins vary in their intracel-
Figure 1. Distinct subsets of signaling proteins are activated by different concentrations of EGF. A–E. Serum-starved A431 cells were
treated for five minutes with different concentrations of EGF, ranging from 250 pM to 32 nM. Phosphorylation levels were determined by
immunoblotting with phosphospecific antibodies and scaled relative to the maximum level observed for each antibody. A. All 12 signaling proteins,
as well as two sites of phosphorylation on EGFR. Error bars indicate the standard error of the mean (SEM) of three biological replicates. Representative
immunoblots are shown for each antibody. B–D. Proteins shown in panel A were divided into three subsets. EGFR tyrosine phosphorylation is shown
in each plot for comparison. Error bars have been omitted for clarity. B. Proteins that are phosphorylated at low concentrations of EGF. C. Proteins
that require high concentrations of EGF to be phosphorylated. D. Proteins with atypical responses. E. A subset of the data from panel A is shown,
highlighting the lowest concentrations of EGF. F. Serum-starved A431 cells were treated for five minutes with different concentrations of EGF, ranging
from 31 pM to 32 nM. Phosphorylation levels were plotted on a log scale to illustrate responses at low EGF concentrations. G. A saturation-binding
curve (inset) was generated for EGF binding to A431 cells. Bound EGF is scaled relative to maximum binding. A Scatchard plot of EGF binding to A431
cells was generated by plotting the ratio of bound-to-free EGF as a function of bound EGF. Error bars indicate the SEM of five biological replicates.
doi:10.1371/journal.pone.0015945.g001
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most of the phosphorylation events fell into only two categories:
phosphorylation induced by low ligand concentrations (Figure 1B)
and phosphorylation induced only by high ligand concentrations
(Figure 1C). The phosphorylation patterns of two cytoplasmic
proteins, SHP-2 and Src, as well as of the receptor at Ser1046/
1047, did not fall into either category (Figure 1D).
The set of proteins comprising Erk, Akt, Shc1, CrkL, Cbl, and
Gab1 was phosphorylated in response to very low concentrations
of EGF. These proteins all showed increased phosphorylation at
even the lowest concentration of EGF and near maximal
phosphorylation at 1 nM EGF. This response was seen both for
the downstream protein Erk, whose activation does not depend on
direct interaction with the receptor, and for the upstream protein
Shc1, which binds directly to the receptor. Thus, the response of
proteins to low concentrations of EGF does not require signal
amplification downstream of receptor activation. In contrast, the
set of proteins comprising Stat1, Stat3, Stat5 and PLCc1 required
higher levels of EGF for activation. At EGF concentrations below
1 nM, there was no detectable induction of phosphorylation of
these proteins (Figure 1, E and F). At higher concentrations,
phosphorylation increased linearly and tracked closely with the
phosphorylation of EGFR on its intracellular tyrosine residues.
Importantly, basal phosphorylation levels of these proteins were
detectable, indicating that the antibodies we used were sensitive
enough to reliably determine the lowest concentration of EGF at
which phosphorylation increased.
To determine if the signaling responses that we observed in
A431 cells were cell line-specific, we examined concentration-
dependent signaling outcomes in three additional cell lines: MDA-
MB-468 breast cancer cells, which, like A431, over-express EGFR
(,10
6 receptors per cell) [18,19]; normal human mammary
epithelial cells (HMECs; ,10
5 receptors per cell) [20]; and human
embryonic kidney cells that were stably transfected with EGFR
(HEK293-EGFR; ,10
5 receptors per cell) [17]. Stimulation of
these three cell lines with different concentrations of EGF revealed
that, in each case, the twelve intracellular signaling proteins could
be divided into the same two groups that respond to either high or
low concentrations of growth factor (Figure 2). We additionally
found that this outcome is not growth factor-specific, as treatment
of A431 or HMEC cells with different concentrations of TGFa
yielded nearly identical results (Figure 2). Together these
observations suggest that there are intrinsic differences in the
receptors that activate these two sets of proteins, and that these
differences are independent of tissue of origin, transformation, or
receptor expression level.
Low-affinity EGF binding is required for PLCc1 and Stat
protein activation
The affinities and relative proportions of high- and low-affinity
receptors that have previously been reported suggest their
involvement in activating the two subsets of signaling proteins
that we observed in our studies. To determine if the cell lines we
used express receptors with two distinct binding affinities, we
measured the direct binding of fluorescently labeled EGF to these
cells and performed Scatchard analysis. The resulting curvilinear
plots (Figure 1G and Figure 3) are characteristic of cells expressing
both high- and low-affinity EGF receptors, and the ratio and
affinities of these binding sites are consistent with previous reports
[5]. These results suggest that many signaling proteins, including
Erk, Akt, Shc1, CrkL, Cbl and Gab1, can be activated by high-
affinity receptors, whereas others, including PLCc1 and the Stat
proteins, are only activated by low-affinity receptors. Because
high- and low-affinity receptors are derived from the same
transcript, it is not possible to selectively mutate or knock down
one population or the other. Additionally, although antibodies that
selectively block either high- or low-affinity binding have been
reported [9,10], in our hands they either activated the receptor or
blocked all ligand binding. We were therefore unable to selectively
perturb one class of receptor to further demonstrate its distinct
signaling properties.
We considered the possibility that PLCc1 and the Stats may
have slower rates of pathway activation than other signaling
proteins and are therefore not phosphorylated in response to low
concentrations of EGF. For example, at low EGF concentrations,
Shc1 might simply out-compete Stat1 for the limited number of
binding sites on activated high-affinity receptors, leading to a
negligible increase in Stat1 phosphorylation after just five minutes
of stimulation. Over time, however, phosphorylated Stat1 could
accumulate as Stat1 slowly gains access to binding sites on EGFR.
To test this alternative hypothesis, we monitored the phosphor-
ylation of cytoplasmic proteins in A431 cells over 30 minutes in
response to either low (1 nM) or high (32 nM) concentrations of
EGF. As anticipated, the intensities of Shc1, Erk, and Akt
phosphorylation were comparable at both concentrations of EGF
(Figure 4). In contrast, whereas high concentrations of EGF
induced robust phosphorylation of PLCc1 and the Stat proteins,
no increase in phosphorylation of these proteins was observed at
low EGF levels, even after 30 minutes of stimulation (Figure 4).
There was even a slight decrease in the basal level of Stat3
phosphorylation, which is likely due to the induction of
phosphatases at low concentrations of EGF. Importantly, at
1 nM EGF, the activity of EGFR, as determined by receptor
phosphorylation at Tyr1173, was approximately 10% of its activity
at 32 nM EGF (Figure 4), demonstrating that this site is
phosphorylated on both high- and low-affinity receptors. These
data are inconsistent with a kinetic explanation and suggest that
the phosphorylation of PLCc1 and the Stat proteins can only be
induced when low-affinity EGF receptors are activated by high
concentrations of EGF. Time-course experiments in HMECs gave
similar results, although signaling was downregulated more rapidly
in these cells (which do not overexpress EGFR) (data not shown).
Some of the cell lines used in this study are known to maintain
autocrine loops that activate EGFR, creating a steady-state level of
signaling through EGFR [21]. This signaling likely occurs through
both high- and low-affinity receptors, due to the high effective
concentration of locally produced ligand. The addition of low
levels of exogenous ligand allows for activation of primarily high-
affinity receptors, while adding higher concentrations of ligand
engages low-affinity receptors as well. Because autocrine signaling
does not appear to saturate signaling through either receptor, the
effects induced by exogenous ligand highlight the different
functions of high- and low-affinity receptors even when low levels
of basal signaling are present.
Low-affinity EGFR induces distinct proliferative responses
EGF was initially identified as a secreted factor that promotes
cellular proliferation. In many cell lines, however, high levels of
EGF have been shown to inhibit proliferation [14]. Depending on
the study, high concentrations of EGF have also been reported to
induce apoptosis [11], cell cycle arrest [12], anoikis [16], or
morphological changes [13] in A431 and MDA-MB-468 cells.
EGF-induced apoptosis has also been observed in MCF-7 cells,
which have substantially lower levels of EGFR (,10
4 receptors per
cell), indicating that anti-proliferative responses are not unique to
cells expressing high levels of EGFR [15].
In order to uncover the roles of high- and low-affinity interactions
in promoting these phenotypes, we investigated the response of
High- and Low-Affinity EGFR
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e15945Figure 2. Distinct subsets of signaling proteins are activated by different concentrations of both EGF and TGFa in multiple cell
lines. Serum-starved cells were treated for five minutes with different concentrations of EGF or TGFa, ranging from 250 pM to 32 nM.
Phosphorylation levels were determined by immunoblotting with phosphospecific antibodies and scaled relative to the maximum level observed for
each antibody.
doi:10.1371/journal.pone.0015945.g002
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PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e15945Figure 3. Cell lines used in this study express receptors with two distinct binding affinities. Saturation binding curves (insets) were
generated for EGF binding to each cell line. Bound EGF is scaled relative to maximum binding. Scatchard plots of EGF binding were generated by
plotting the ratio of bound-to-free EGF as a function of bound EGF. Error bars indicate the range of two biological replicates for MDA-MB-468,
HEK293-EGFR, and A431 cells and the SEM of three biological replicates for HMECs.
doi:10.1371/journal.pone.0015945.g003
Figure 4. Stat proteins and PLCc1 cannot be activated by low EGF concentrations in A431 cells. Serum-starved A431 cells were treated
with either 1 nM or 32 nM EGF. Phosphorylation of EGFR and downstream signaling proteins was monitored over the course of 30 minutes by
quantitative immunoblotting. PLCc1 and the Stat proteins were only activated at the high concentration of EGF (32 nM). All other signaling proteins
were activated at both high (32 nM) and low (1 nM) concentrations of EGF. Phosphorylation levels were scaled relative to the maximum signal
observed for each antibody. Error bars indicate the range of two biological replicates.
doi:10.1371/journal.pone.0015945.g004
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e15945Figure 5. High and low concentrations of EGF induce distinct phenotypic outcomes. A. Serum-starved A431 cells were treated with 0 nM,
0.5 nM or 16 nM EGF. At the indicated times, cells were trypsinized and counted. Error bars represent the SEM of three biological replicates. B. Left,
A431 cells were serum-starved for 24 hours and treated with different concentrations of EGF for 12 hours. BrdU was added to the culture medium for
High- and Low-Affinity EGFR
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with either 0.5 nM or 16 nM EGF and counted over a three-day
period. After 16 hours, treatment with 16 nM EGF resulted in a
reduction in cell number, whereas treatment with 0.5 nM EGF
induced cell proliferation (Figure 5A). At longer time points, cells
treated with 16 nM EGF began to increase in number, but the total
number of cells remained lower than was observed in serum-free
medium or in 0.5 nM EGF. We observed no evidence of EGF-
induced apoptosis under these conditions (data now shown).
To investigate more precisely the role of high- and low-affinity
EGF receptors in cell proliferation, we monitored BrdU incorpo-
ration after treating A431 cells for twelve hours with different
concentrations of EGF. Cell proliferation increased in a dose-
dependent manner for concentrations up to and including 0.5 nM
EGF (Figure 5B). This increase corresponded with a sharp rise in
Erk phosphorylation, which is representative of signaling by high-
affinity receptors (Figure 5B). The rise in BrdU incorporation
leveled-off between 1 and 2 nM EGF and then decreased in a dose-
dependent manner at higher concentrations. This decrease in DNA
synthesiscoincidedwiththeonsetofStat1phosphorylation,whichis
representative ofsignalingbylow-affinityreceptorsand isthoughtto
play an important role in the anti-proliferative effects of EGF
(Figure 5B) [12]. To determine if our results can be generalized to
more heterogeneous extracellular environments, we repeated our
EGF stimulations using cells grown in media containing 10%
serum. We found that both the binding and signaling data were
almost identical to data generated under serum-free conditions
(Figure 3 and data not shown). Further, when BrdU incorporation
assays were performed with different concentrations of EGF, we
observed a proliferative response that mirrored the response in
serum-free medium (Figure 5C). Notably, at higher ligand
concentrations, the observed anti-proliferative response was even
morepronounced than when the cells weregrown under serum-free
conditions, as the levels of BrdU incorporation dropped well below
basal levels. Receptor downregulaton might contribute to the
observed inhibition of proliferation at high concentrations of EGF.
However, the activation of Stat1 exclusively by low-affinity
receptors at short time points (Figure 1) before downregulation
occurs, combined with the known role of Stat1 in mediating EGF-
induced growth inhibition [12,22], argues that specific signaling
events in response to high EGF concentrations induce the negative
effect on proliferation. These results demonstrate that signaling by
high-affinity EGF receptors favors cell proliferation, whereas
signaling by low-affinity EGF receptors inhibits this response, not
by decreasing signaling through Erk, but by eliciting a distinct set of
opposing signals.
Low-affinity EGFR alters cellular adhesion properties
In addition to the anti-proliferative effects, we found that the
collective morphology of A431 cells was altered at EGF
concentrations that engage low-affinity receptors. At low concen-
trations of EGF, cultured cells proliferated and formed a confluent
monolayer. Strikingly, at concentrations of EGF above 2 nM, cells
clustered into three-dimensional islands and grew on top of each
other (Figure 6A). This adhesion response was observed within two
hours of adding EGF, and the effect became more pronounced
with increasing EGF concentrations, mirroring the concentration-
dependent decrease in cell proliferation. Cell clustering was
observed both when the cells were grown under serum-free
conditions (Figure 6A) and when they were grown in 10% serum
(Figure 6B). Changes in integrin levels, which can be regulated by
Stat3 [23], have previously been implicated in cell clustering [13].
The EGF concentrations at which the clustered morphology was
induced and the potential involvement of Stat3 argue that, in
addition to inhibiting cell proliferation, low-affinity receptors also
mediate changes in cell adhesion properties.
Discussion
Our studies provide evidence that low-affinity EGF receptors
play crucial roles in cell-fate decisions. EGF titrations demonstrate
the existence of two distinct sets of cytoplasmic signaling proteins:
Figure 6. Activation of low-affinity EGFR alters cellular adhesion properties. Phase-contrast images of A431 cells treated with different
concentrations of EGF for 12 hours. A. Serum-starved cells. B. Cells grown in 10% serum. Onset of the cell clumping phenotype coincides with Stat
phosphorylation.
doi:10.1371/journal.pone.0015945.g006
the last hour of the EGF incubation. Cell proliferation was recorded as the change in the percentage of BrdU-positive cells relative to unstimulated
cells (no EGF). Error bars represent the SEM of three biological replicates. Right, the cell proliferation data overlaid with the relative phosphorylation
levels of Erk and Stat1 as reported in Fig. 1. Error bars have been omitted for clarity. The decrease in proliferation coincides with the increase in Stat1
phosphorylation. C. Left, A431 cells grown in 10% serum were treated with different concentrations of EGF for 24 hours and BrdU incorporation was
determined as in B. Right, the cell proliferation data overlaid with the relative phosphorylation levels of Erk and Stat1 in these cells. Error bars have
been omitted for clarity.
doi:10.1371/journal.pone.0015945.g005
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small fraction of EGFR molecules are active, and a second,
comprising PLCc1, Stat1, Stat3 and Stat5, that is only activated
by higher concentrations of EGF. These results, in conjunction
with the observed affinities and ratios of high- and low-affinity
receptors, strongly suggest that although many signaling pathways
can be activated by high-affinity EGF receptors, PLCc1 and the
Stat proteins depend on low-affinity receptors for their activation.
In addition to the concentration-dependent signaling profiles,
changes in cell morphology and rates of proliferation coincide with
the activation of low-affinity receptors, supporting a role for these
receptors in determining phenotypic outcome. Some of the cell
lines used in this study maintain autocrine loops that activate
EGFR even under serum-starved conditions. While this prohibits
the complete elimination of negative feedback loops, the
experimental setup using exogenous ligand demonstrates that
even in the presence of a basal level of signaling, EGF receptors
have distinct functions that are based on their ligand affinity.
Accordingly, our data are very similar when cells are grown in the
presence of serum, demonstrating that our findings hold true even
in a more complex signaling environment.
It has been known for some time that cells exhibit different
phenotypic responses to high and low concentrations of EGF. It is
alsowell known that EGFR appears to exist intwodifferent forms: a
high-affinity form with an apparent KD of <300 pM, and a low
affinity form with an apparent KD of <2 nM. To date, however,
these two observations have not been linked to signaling outputs, as
high- and low-affinity EGF receptors have never been shown to
elicit specific and distinct intracellular signaling events. Here, we
provide evidence that low-affinity EGF receptors activate a distinct
set of intracellular signaling proteins (the Stat proteins and PLC-c)
and that the concentration of EGF or TGFa at which this occurs
coincides precisely with the point at which different phenotypic
outcomes are observed. To date, all mathematical models of EGFR
signaling assume that the activated receptor exists in a single form
and turns on a specific set of signaling proteins. These models are
unable to predict the different phenotypic outcomes that are
observed at different ligand concentrations. Our study provides
evidence that low-affinity receptors turn on specific and distinct
signaling pathways and argues strongly that predictive models of
EGFR signaling should take low-affinity receptors into account.
While we would have liked to inhibit each form of the receptor
independently, unfortunately there is currently no way to
selectively perturb either the high- or low-affinity population of
receptors, as they are both encoded by the same transcript. As
there was no way to selectively perturb either population, we relied
on extremely rigorous and quantitative analyses to observe
coincidence between the three phenomena we were studying:
ligand binding, activation of signaling proteins, and phenotypic
outcome. These studies were performed in a variety of cell lines,
both normal and transformed, that exhibited a range of receptor
expression levels; they were performed with two different ligands
(EGF and TGFa); and they were performed in the presence and
absence of serum to control for environmental factors. We went to
great lengths to ensure that these observations are not isolated
phenomena, but are indeed intrinsic to the receptor, independent
of its immediate environment.
It is unclear whether the average concentration of EGF in any
tissue ever approaches the concentration required to activate low-
affinity receptors. However, in cases of autocrine signaling, the
effective concentration of EGFR ligands in the immediate vicinity
of cell-surface receptors likely exceeds this threshold. Squamous
cell carcinomas of the head and neck often rely on the activation of
Stat3 for proliferation and survival [24]. Stat3 activity in these
cancer cells has been shown to depend on autocrine activation of
EGFR by secreted TGFa [24,25]. The fact that Stat3 is only
activated by low-affinity receptors in every cell type that we
examined suggests that in vivo concentrations of EGFR ligands can
stimulate low-affinity receptors and identifies a possible role for
low-affinity receptors in the in vivo signaling of cancer cells.
Very recently, structural studies of the extracellular ligand-
binding domain of Drosophila EGFR have supported negative
cooperativity in ligand binding [26]. The authors showed that the
first ligand binds with high affinity and induces a conformational
change that promotes asymmetry in the dimer. The conformational
change restrains the vacant binding site such that its affinity for
bindingthesecond ligandis reduced.High- and low-affinitybinding
sites therefore occur in the same receptor dimer and result from
negative cooperativity rather than from distinct populations of
receptor. The authors further argue that the second binding event
must compromise either ligand-receptor or receptor-receptor
contacts, and that therefore a doubly occupied dimer could have
different interactionsand signaling properties than a singlyoccupied
one. Although this asymmetry has not been observed in the
extracellular domain of human EGFR, a similar mode of regulation
remains possible. If high- and low-affinity interactions do arise from
negative cooperativity, singly-occupied dimers should be most
abundant at low concentrations of ligand, and doubly occupied
dimers should only form at higher concentrations of ligand. It is
therefore possible that the Stat proteins and PLCc1 can only be
activated by doubly occupied dimers that have altered specificity,
autophosphorylation or interactions.
EGFR has been extensively studied over the past three decades,
and several recent analyses have provided system-level views and
models of signaling downstream of the receptor [27–30]. These
studies, however, have not accounted for the distinct signaling
properties of high- and low-affinity receptors. In addition to the
biological implications, our findings should benefit computational
efforts to model this signaling network and predict cellular
outcomes in response to diverse stimuli.
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